Drospirenone, a progestogen with antimineralocorticoid properties: A short review

Molecular and Cellular Endocrinology

Volumn 217, Issue 1-2, 2004, Pages 255-261

  Oelkers, Wolfgang ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Aldosterone; Body fluids; Drospirenone; Estrogens; Mineralocorticoids; Progestogens

Indexed keywords

ANTIANDROGEN; ANTIHYPERTENSIVE AGENT; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; STEROID RECEPTOR;

ACNE VULGARIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; EXPERIMENTAL RAT; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERTENSION; MENOPAUSAL SYNDROME; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; WEIGHT REDUCTION;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGESTERONE; RABBITS; RATS; RECEPTORS, MINERALOCORTICOID; WEIGHT GAIN;

EID: 2342563102     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.030     Document Type: Conference Paper

References (18)

1. Blode H., Wuttke W., Loock W., Röll G., Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur. J. Contracept. Reprod. Health Care. 5(Suppl. 3):2000;256-264
2. Brown C., Ling F., Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenopausal symptoms. J. Reprod. Med. 47:2002;14-22
3. Crane, M.G., Harris, J.J., 1974a. Effect of estrogens and gestagens on the renin-angiotensin-aldosterone system and on plasma transcortin in women and men. In: Fregly, M.J., Fregly, M.S. (Eds.), Oral Contraceptives and High Blood Pressure. Dolphin Press, Gainesville, pp. 100-119.
4. Crane, M.G., Harris, J.J., 1974b. Effect of estrogens and gestagens on exchangeable sodium. In: Fregly, M.J., Fregly, M.S. (Eds.), Oral Contraceptives and High Blood Pressure. Dolphin Press, Gainesville, pp. 159-168.
5. Foidart J.M. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur. J. Contracept. Reprod. Health Care. 5(Suppl. 3):2000;25-33
6. ® in the management of premenstrual dysphoric disorder. Eur. J. Contracept. Reprod. Health Care. 7(Suppl. 3):2002;25-33
7. Muhn, P., Fuhrmann, U., Fritzemeier, K.H., Krattenmacher, R., Schillinger, E., 1995. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. In: Steroid Receptors and Antihormones. Ann. N.Y. Acad. Sci. 761, 311-331.
8. Nichols M., Robinson G., Bounds W., Newman B., Guillebaud J. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception. 47:1993;367-376
9. Oelkers W. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 61:1996;166-171
10. Oelkers W., Berger V., Bolik A., Bähr V., Hazard B., Beyer S., Elger W., Heithecker R. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J. Clin. Endocrinol. Metab. 73:1991;837-842
11. Oelkers W., Blümel A., Schwartz U., Hammerstein J. Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J. Clin. Endocrinol. Metab. 43:1976;1036-1040
12. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab. 80:1995;1816-1821
13. Oelkers W., Schöneshöfer M., Blümel A. Effects of progesterone and four synthetic progestogens on sodium balance and the renin-aldosterone system in man. J. Clin. Endocrinol. Metab. 39:1974;882-889
14. Oelkers W., Schöneshöfer M., Schultze G., Wenzler M., Bauer B., Láge M., Fehm H.L. Prolonged infusions of Ile-5-angiotensin II in sodium replete and deplete man: effects on aldosterone, ACTH, cortisol, blood pressure and electrolyte balance. J. Clin. Endocrinol. Metab. 46:1978;402-413
15. Pollow K., Jucham N., Elger W., Jacobi N., Hoffmann G., Möbus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen. Characterization of binding to different binding proteins. Contraception. 46:1992;561-574
16. Rosenbaum P., Schmidt W., Helmerhorst F.M., Wuttke W., Rossmanith W., Freundl F., Thomas K., Grillo M., Wolf A., Heithecker R. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur. J. Contracept. Reprod. Health Care. 5:2000;16-24
17. Saruta T., Saade G.A., Nagahama S., Suzuki H., Kondo K. Effects of an angiotensin II analog on blood pressure, renin and aldosterone in women on oral contraceptives and in toxemia. Gynecol. Obstet. Invest. 12:1981;11-20
18. Writing group for the Women's Health Initiative Investigators, 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. J. Am. Med. Assoc. 288, 321-333.